Global Innovative Biologics Market Research Report 2024

Publication ID:

PB507248862

Publication Date:

July 3, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
The global Innovative Biologics market was valued at US$ 465440 million in 2023 and is anticipated to reach US$ 657710 million by 2030, witnessing a CAGR of 8.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Innovative Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Innovative Biologics.
Report Scope
The Innovative Biologics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Innovative Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Innovative Biologics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Sobi
Changchun High Tech
Kanghong Pharma
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Innovative Biologics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Innovative Biologics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Innovative Biologics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Innovative Biologics Market Perspective (2019-2030)
2.2 Innovative Biologics Growth Trends by Region
2.2.1 Global Innovative Biologics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Innovative Biologics Historic Market Size by Region (2019-2024)
2.2.3 Innovative Biologics Forecasted Market Size by Region (2025-2030)
2.3 Innovative Biologics Market Dynamics
2.3.1 Innovative Biologics Industry Trends
2.3.2 Innovative Biologics Market Drivers
2.3.3 Innovative Biologics Market Challenges
2.3.4 Innovative Biologics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Innovative Biologics Players by Revenue
3.1.1 Global Top Innovative Biologics Players by Revenue (2019-2024)
3.1.2 Global Innovative Biologics Revenue Market Share by Players (2019-2024)
3.2 Global Innovative Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Innovative Biologics Revenue
3.4 Global Innovative Biologics Market Concentration Ratio
3.4.1 Global Innovative Biologics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Innovative Biologics Revenue in 2023
3.5 Innovative Biologics Key Players Head office and Area Served
3.6 Key Players Innovative Biologics Product Solution and Service
3.7 Date of Enter into Innovative Biologics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Innovative Biologics Breakdown Data by Type
4.1 Global Innovative Biologics Historic Market Size by Type (2019-2024)
4.2 Global Innovative Biologics Forecasted Market Size by Type (2025-2030)
5 Innovative Biologics Breakdown Data by Application
5.1 Global Innovative Biologics Historic Market Size by Application (2019-2024)
5.2 Global Innovative Biologics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Innovative Biologics Market Size (2019-2030)
6.2 North America Innovative Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Innovative Biologics Market Size by Country (2019-2024)
6.4 North America Innovative Biologics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Innovative Biologics Market Size (2019-2030)
7.2 Europe Innovative Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Innovative Biologics Market Size by Country (2019-2024)
7.4 Europe Innovative Biologics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Innovative Biologics Market Size (2019-2030)
8.2 Asia-Pacific Innovative Biologics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Innovative Biologics Market Size by Region (2019-2024)
8.4 Asia-Pacific Innovative Biologics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Innovative Biologics Market Size (2019-2030)
9.2 Latin America Innovative Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Innovative Biologics Market Size by Country (2019-2024)
9.4 Latin America Innovative Biologics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Innovative Biologics Market Size (2019-2030)
10.2 Middle East & Africa Innovative Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Innovative Biologics Market Size by Country (2019-2024)
10.4 Middle East & Africa Innovative Biologics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Innovative Biologics Introduction
11.1.4 Roche Revenue in Innovative Biologics Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Innovative Biologics Introduction
11.2.4 Amgen Revenue in Innovative Biologics Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Innovative Biologics Introduction
11.3.4 AbbVie Revenue in Innovative Biologics Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Innovative Biologics Introduction
11.4.4 Sanofi Revenue in Innovative Biologics Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Innovative Biologics Introduction
11.5.4 Johnson & Johnson Revenue in Innovative Biologics Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Innovative Biologics Introduction
11.6.4 Pfizer Revenue in Innovative Biologics Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Detail
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Innovative Biologics Introduction
11.7.4 Novo Nordisk Revenue in Innovative Biologics Business (2019-2024)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Detail
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Innovative Biologics Introduction
11.8.4 Eli Lilly Revenue in Innovative Biologics Business (2019-2024)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Innovative Biologics Introduction
11.9.4 Novartis Revenue in Innovative Biologics Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Innovative Biologics Introduction
11.10.4 Merck Revenue in Innovative Biologics Business (2019-2024)
11.10.5 Merck Recent Development
11.11 Biogen
11.11.1 Biogen Company Detail
11.11.2 Biogen Business Overview
11.11.3 Biogen Innovative Biologics Introduction
11.11.4 Biogen Revenue in Innovative Biologics Business (2019-2024)
11.11.5 Biogen Recent Development
11.12 Sobi
11.12.1 Sobi Company Detail
11.12.2 Sobi Business Overview
11.12.3 Sobi Innovative Biologics Introduction
11.12.4 Sobi Revenue in Innovative Biologics Business (2019-2024)
11.12.5 Sobi Recent Development
11.13 Changchun High Tech
11.13.1 Changchun High Tech Company Detail
11.13.2 Changchun High Tech Business Overview
11.13.3 Changchun High Tech Innovative Biologics Introduction
11.13.4 Changchun High Tech Revenue in Innovative Biologics Business (2019-2024)
11.13.5 Changchun High Tech Recent Development
11.14 Kanghong Pharma
11.14.1 Kanghong Pharma Company Detail
11.14.2 Kanghong Pharma Business Overview
11.14.3 Kanghong Pharma Innovative Biologics Introduction
11.14.4 Kanghong Pharma Revenue in Innovative Biologics Business (2019-2024)
11.14.5 Kanghong Pharma Recent Development
11.15 Gan&Lee
11.15.1 Gan&Lee Company Detail
11.15.2 Gan&Lee Business Overview
11.15.3 Gan&Lee Innovative Biologics Introduction
11.15.4 Gan&Lee Revenue in Innovative Biologics Business (2019-2024)
11.15.5 Gan&Lee Recent Development
11.16 Tonghua Dongbao
11.16.1 Tonghua Dongbao Company Detail
11.16.2 Tonghua Dongbao Business Overview
11.16.3 Tonghua Dongbao Innovative Biologics Introduction
11.16.4 Tonghua Dongbao Revenue in Innovative Biologics Business (2019-2024)
11.16.5 Tonghua Dongbao Recent Development
11.17 United Laboratory
11.17.1 United Laboratory Company Detail
11.17.2 United Laboratory Business Overview
11.17.3 United Laboratory Innovative Biologics Introduction
11.17.4 United Laboratory Revenue in Innovative Biologics Business (2019-2024)
11.17.5 United Laboratory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Sobi
Changchun High Tech
Kanghong Pharma
Gan&Lee
Tonghua Dongbao
United Laboratory

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂